

Encorafenib plus cetuximab in patients with *BRAF*^{V600E}-mutated metastatic colorectal cancer — Polish multicenter experience

To the Editor:

Because of our mistake in defining treatment time as well as in data on progression-free survival (PFS), we wish to retract the following article: Encorafenib plus cetuximab in patients with *BRAF*^{V600E}-mutated metastatic colorectal cancer — Polish multicenter experience. *Oncol. Clin. Pract.* 2023; DOI: 10.5603/ocp.96898.

After our communication with the Editors, we have reanalyzed the data and have published a new report: Encorafenib plus cetuximab in patients with *BRAF*^{V600E}-mutated metastatic colorectal cancer — Polish multicenter experience. *Oncol. Clin. Pract.* 2023; DOI: 10.5603/ocp.98519.

Marek Gefej^{1, 2}, Patryk Zając^{2, 3}, Maria Dąbrowska⁴, Anna Dejws-Wątróbowska⁵, Bogumiła Galińska⁶, Łukasz Galus⁷, Agnieszka Gwóźdź-Cieślak⁸, Katarzyna Hetman⁵, Maciej Kawecki⁹, Mateusz Malik¹⁰, Joanna Streb¹¹, Katarzyna Wierzbicka¹², Piotr Wiosek¹³, Barbara Radecka^{1, 2}

¹Department of Oncology, Institute of Medical Sciences, University of Opole in Opole, Poland

²Oncology Clinic with Daily Ward, Opole Oncology Center of Prof. Tadeusz Koszarowski in Opole, Poland

³Department of Clinical Biochemistry and Laboratory Diagnostics, Faculty of Medicine, University of Opole in Opole, Poland

⁴Department of Clinical Oncology, Provincial Specialist Hospital No. 4, Bytom, Poland

⁵Department of Clinical Oncology, West Pomeranian Oncology Center, Szczecin, Poland

⁶Independent Public Clinical Hospital No. 1 of Prof. Tadeusz Sokołowski, Pomeranian Medical University, Szczecin, Poland

⁷Department of Clinical and Experimental Oncology, Institute of Oncology, Medical University of Poznań, Poland

⁸Department of Clinical Oncology, Świętokrzyskie Cancer Center, Kielce, Poland

⁹Department of Oncology and Radiotherapy, National Institute of Oncology. Maria Skłodowska-Curie — National Research Institute, Warsaw, Poland

¹⁰Department of Clinical Oncology, Lower Silesian Center of Oncology, Pulmonology and Hematology, Wrocław, Poland

¹¹Department of Oncology, Jagiellonian University, Krakow, Poland

¹²Department of Oncology and Radiotherapy, University Clinical Center, Gdańsk, Poland

¹³Oncology Department, Provincial Hospital, Elbląg, Poland

This letter was published on December 20, 2023.

Editor's note:

In their initial analysis, while calculating median progression-free survival (PFS), the authors did not include data from 2 patients in whom disease progression had been confirmed. In consequence, the authors reported that median PFS had not been reached. After the authors' subsequent review of their data, inclusive of the omitted patients, median PFS of 7.1 months was calculated. Additionally, the median treatment time, wrongly presented as 7 weeks, was replaced by the median number of treatment cycles. The authors have confirmed that the percentage of disease control was 76.4% and that analyzed patients did not receive treatment after progression, so, in fact, the treatment time was the same as the follow-up time in every patient. The conclusions drawn after data re-analysis remain in force. Missing information on research funding has been supplemented.